Professor QIU Ming-Hua and his group has isolated and identified 164 compounds, including 40 new constituents, 2 of which have novel skeleton, from six samples which are the rhizome of Cimicifuga foetida L and Cimicifuga yunnanensis H collected from Dali, Lijiang in Yunnan and Weining in Guizhou. Cooperating with Kunming Medical College, the group tested those compounds’ cytotoxicities against different human cell lines and found that compounds K-5, K-6, K-314 and DK-314 showed significant activities. The vivo activities of K-314 and DK-314 have been tested on the mice and nude mice models and the results showed that this two compounds can significantly inhibited the growth of solid tumors and are potential anticancer drugs. The group also explored the preliminarily technology of the preparation and the structure-activity relationships of the tested compounds, and established the testing methods and quality control standards for crud drugs, its extracts, active fractions and active compounds. In addition, they assessed the inhibitory effect of 14 triterpenoids on human drug resistant breast cancer cells and found that compounds KCY14, KCY49 and KYY20 had potent acitivies, with IC50 values of 5.29, 4.81 and 4.81μg/ml, respectively, which were as equal as the positive control TAXOL (IC50 4.81μg/ml). The research applied for 6 national invention patents and 4 were authorized, published 10 academic papers and nine were in SCI. They have trained 4 doctors and 4 masters.

 

Influence of Actein and Deoxyactein on the growth of

 mice transplanted Sarcoma S180